Drug Interaction Safety: Trazodone with Propafenone

Critical Drug Interaction Concern

Trazodone requires caution in patients with premature ventricular contractions and has documented cardiac effects, according to the American Academy of Family Physicians 1
Propafenone causes QT interval prolongation and requires ECG monitoring, with discontinuation recommended if QT interval exceeds 500 ms, as stated by the European Society of Cardiology 2
The combination of trazodone and propafenone is not explicitly contraindicated in major guidelines, but the U.S. Public Health Service guidelines specifically list propafenone alongside other antiarrhythmics as requiring caution with drugs that affect cardiac conduction 3

The patient has no structural heart disease, which is a contraindication for propafenone, as noted by the European Society of Cardiology 2
Baseline ECG shows QTc <450 ms and no conduction abnormalities, as recommended by the European Society of Cardiology 2
The patient has no history of ventricular arrhythmias beyond isolated premature ventricular contractions, according to the American Academy of Family Physicians 1
No other QT-prolonging medications are being used concurrently, as advised by the European Society of Cardiology 2

Obtain a baseline ECG before starting trazodone if the patient is already on propafenone, specifically checking QTc interval, QRS duration, and PR interval, as recommended by the European Society of Cardiology 2
Repeat ECG at 1-2 weeks after initiating trazodone to assess for QTc prolongation >500 ms and new conduction abnormalities, as stated by the European Society of Cardiology 2

Consider alternative sleep agents with no cardiac effects, such as ramelteon, suvorexant, or low-dose doxepin, as suggested by the American Academy of Family Physicians 4
Avoid benzodiazepines in elderly patients due to cognitive impairment risk, as advised by the American Academy of Family Physicians 4

Patient has structural heart disease, ischemic heart disease, or reduced ejection fraction, which is a contraindication for propafenone, as noted by the European Society of Cardiology 2
Baseline QTc >450 ms, as stated by the European Society of Cardiology 2
Patient is on other QT-prolonging drugs, such as antipsychotics, macrolide antibiotics, or azole antifungals, as advised by the European Society of Cardiology and the U.S. Public Health Service 2, 3

La dosis máxima diaria de propafenona es de 900 mg/día (300 mg cada 8 horas) para la formulación de liberación inmediata y 850 mg/día (425 mg cada 12 horas) para la formulación de liberación prolongada en el manejo ambulatorio crónico, según el American College of Cardiology 5, 6, 7
Hasta 1200 mg/día puede considerarse en un entorno de monitoreo hospitalario como dosis de carga, pero esto debe limitarse estrictamente al ámbito intrahospitalario con vigilancia continua, según el American College of Cardiology 5, 6
La American College of Cardiology y la Circulation recomiendan que la utilidad y seguridad de dosis superiores a 900 mg por día no han sido establecidas 5, 6, 7, 8
600 mg como dosis única oral para cardioversión farmacológica de fibrilación auricular de inicio reciente, según la Circulation 9, 10

Disfunción hepática es una contraindicación relativa; usar con extrema precaución, según el American College of Cardiology y la Circulation 5, 6, 7, 8
Enfermedad cardíaca estructural (incluyendo cardiopatía isquémica): Evitar o usar con extrema precaución, según el American College of Cardiology y la Circulation 5, 6, 7, 8
Insuficiencia cardíaca o disfunción ventricular izquierda severa: Contraindicado, según el American College of Cardiology y la Circulation 5, 6, 7, 8
Disfunción del nodo sinusal o AV (sin marcapasos): Contraindicado, según el American College of Cardiology y la Circulation 5, 6, 7, 8
Síndrome de Brugada: Contraindicado (puede desenmascarar el patrón), según el American College of Cardiology y la Circulation 5, 6, 7, 8

Amiodarona: Reduce la dosis de propafenona en 30-50%, según el American College of Cardiology 5, 6
Inhibidores del CYP2D6 (quinidina, fluoxetina, antidepresivos tricíclicos): Aumentan las concentraciones plasmáticas y el efecto beta-bloqueante, según la Circulation 11
Digoxina: La propafenona aumenta los niveles de digoxina en 30-50%; monitorear concentraciones, según el American College of Cardiology y la Circulation 5, 6, 8
Warfarina: La propafenona aumenta el INR en aproximadamente 25%, según la Circulation 11